Drug intelligence / Profile preview

KBD061

Development stage: Preclinical
Lead developer: Baiyu Pharmaceutical
Modality: Small Molecules

Overview

KBD061 is an investigational small molecule oncology candidate developed by Chengdu Baiyu Jingelai Pharmaceutical. It is designed to treat solid tumors by modulating pathways associated with DNA damage and repair. While the specific molecular target within the DNA damage response (DDR) framework remains undisclosed by the developer, the drug is positioned as a targeted therapy for various malignancies. It is currently in the early stages of development, appearing in the company's research and development pipeline.

Beyond the preview

Go deeper on KBD061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD061.

Explore the full profile